<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2951">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01457703</url>
  </required_header>
  <id_info>
    <org_study_id>09-0977</org_study_id>
    <secondary_id>U54HD058155</secondary_id>
    <nct_id>NCT01457703</nct_id>
  </id_info>
  <brief_title>Reproductive Hormonal Alterations in Obesity</brief_title>
  <official_title>Reproductive Hormonal Alterations in Obesity, AIMS #1 &amp; #2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine why obese women have lower hormone levels and less
      fertility than women of normal body weight. The proposal will examine the reproductive
      system at the level of the brain and the ovary to define the changes that happen leading to
      lowered hormone production. Women will be studied throughout a menstrual cycle and given
      medications that will test how well their pituitary gland can make hormones that stimulate
      the ovary (luteinizing hormone (LH) and follicle stimulating hormone (FSH)). They will also
      be given a medication to abolish estrogen production in the body and their response to this
      medication will be assessed. Finally, the ovary's ability to produce progesterone after
      ovulation will be examined.

      --Hypotheses:

        1. Obese women have reduced pituitary sensitivity to exogenous gonadotropin-releasing
           hormone (GnRH), but normal clearance of exogenous LH. (comparative study of obese
           compared to normal weight women)

        2. Obese women have abnormally increased sensitivity to estradiol negative feedback which
           will be reversed by an aromatase inhibitor. (comparative study of obese compared to
           normal weight women)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM 1: test the hypothesis that reduced pituitary sensitivity to GnRH-induced LH and FSH
      secretion causes the relative hypogonadotropic hypogonadism of obesity AIM 2: test the
      hypothesis that the hypothalamic-pituitary axis is abnormally sensitive to estradiol
      negative feedback in obesity
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Luteinizing Hormone (LH) Pulsatility</measure>
    <time_frame>Averaged over the luteal phase of the cycle</time_frame>
    <safety_issue>No</safety_issue>
    <description>Endogenous hypothalamic-pituitary function (as measured by LH pulsatility) was compared between the obese and normal weight groups. Luteinizing hormone pulsatility (Luteinizing Hormone (LH) Pulse Amplitude) was evaluated using a modified Santen-Bardin method (frequent blood sampling).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2:
BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrorelix</intervention_name>
    <description>Abolishes pituitary sensitivity to GnRH.</description>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <other_name>Cetrotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadorelin-GnRH</intervention_name>
    <description>GnRH is used to stimulate the pituitary gland to produce LH and FSH.</description>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <other_name>Lutrepulse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant LH</intervention_name>
    <description>Used to stimulate ovarian function in women.</description>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <other_name>Luveris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>An aromatase inhibitor.</description>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-40 at study entry

          -  BMI either 18-25 kg/m2 or ≥30 kg/m2

          -  prolactin (PRL) and thyroid-stimulating hormone (TSH) within normal laboratory ranges
             at screening

          -  Baseline hemoglobin &gt;11 gm/dl

          -  History of regular menstrual cycles every 25-35 days if BMI 18-25 kg/m2

          -  History of regular menstrual cycles every 25-40 days if BMI ≥30 kg/m2

        Exclusion Criteria:

          -  History of chronic disease affecting hormone production, metabolism or clearance

          -  Use of medications that are known to alter or interact with reproductive hormones
             (e.g., thiazolidinediones, metformin)

          -  Use of hormones within three months of enrollment

          -  Excessive exercise (&gt;4 hours per week)

          -  Pregnancy, breast-feeding or current active attempts to conceive
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nanette Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Translational Research Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cudoctors.com/find-a-doctor/profile/?providerID=3067&amp;name=santoro</url>
    <description>PI Biographical data</description>
  </link>
  <reference>
    <citation>Jain A, Polotsky AJ, Rochester D, Berga SL, Loucks T, Zeitlian G, Gibbs K, Polotsky HN, Feng S, Isaac B, Santoro N. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab. 2007 Jul;92(7):2468-73. Epub 2007 Apr 17.</citation>
    <PMID>17440019</PMID>
  </reference>
  <reference>
    <citation>Haynes G, Bailey MK, Davis S, Mahaffey JE. Use of methylprednisolone in epidural analgesia. Arch Neurol. 1989 Nov;46(11):1167-8.</citation>
    <PMID>2818247</PMID>
  </reference>
  <reference>
    <citation>Rochester D, Jain A, Polotsky AJ, Polotsky H, Gibbs K, Isaac B, Zeitlian G, Hickmon C, Feng S, Santoro N. Partial recovery of luteal function after bariatric surgery in obese women. Fertil Steril. 2009 Oct;92(4):1410-5. doi: 10.1016/j.fertnstert.2008.08.025. Epub 2008 Sep 30.</citation>
    <PMID>18829008</PMID>
  </reference>
  <reference>
    <citation>Santen RJ, Bardin CW. Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms. J Clin Invest. 1973 Oct;52(10):2617-28.</citation>
    <PMID>4729055</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 24, 2015</lastchanged_date>
  <firstreceived_date>September 21, 2011</firstreceived_date>
  <firstreceived_results_date>June 19, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LH pulsatility</keyword>
  <keyword>Obesity</keyword>
  <keyword>Reproduction</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BMI ≥30 kg/m2</title>
          <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
        <group group_id="P2">
          <title>BMI 18-25 kg/m2</title>
          <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BMI ≥30 kg/m2</title>
          <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
        <group group_id="B2">
          <title>BMI 18-25 kg/m2</title>
          <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="62"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="62"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="52"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Luteinizing Hormone (LH) Pulsatility</title>
        <description>Endogenous hypothalamic-pituitary function (as measured by LH pulsatility) was compared between the obese and normal weight groups. Luteinizing hormone pulsatility (Luteinizing Hormone (LH) Pulse Amplitude) was evaluated using a modified Santen-Bardin method (frequent blood sampling).</description>
        <time_frame>Averaged over the luteal phase of the cycle</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BMI ≥30 kg/m2</title>
            <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
          </group>
          <group group_id="O2">
            <title>BMI 18-25 kg/m2</title>
            <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Luteinizing Hormone (LH) Pulsatility</title>
            <description>Endogenous hypothalamic-pituitary function (as measured by LH pulsatility) was compared between the obese and normal weight groups. Luteinizing hormone pulsatility (Luteinizing Hormone (LH) Pulse Amplitude) was evaluated using a modified Santen-Bardin method (frequent blood sampling).</description>
            <units>IU/L</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.1" lower_limit="2.9" upper_limit="5.2"/>
                  <measurement group_id="O2" value="3.6" lower_limit="2.7" upper_limit="9.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BMI ≥30 kg/m2</title>
          <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
        <group group_id="E2">
          <title>BMI 18-25 kg/m2</title>
          <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Regulatory Manager</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303-724-6501</phone>
      <email>Chanel.mansfield@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
